Kanwal P.S. Raghav, MBBS, MD

Peer-Reviewed Articles

1. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol 33(31):3583-90, 2015. e-Pub 2015. PMID: 26304898.
2. Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer 121(17):2968-75, 2015. e-Pub 2015. PMID: 25975416.
3. Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP Scoring System for Assessing Hepatic Reserve in Egyptian Patients with Hepatocellular Carcinoma. Oncotarget 6(25):21193-207, 2015. PMID: 26098859.
4. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
5. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 106(5), 2014. e-Pub 2014. PMID: 24815863.
6. Raghav K, Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms. Nat Rev Clin Oncol 10(9):534-44, 2013. e-Pub 2013. PMID: 23897080.
7. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist 18(12):1270-7, 2013. e-Pub 2013. PMID: 24149137.
8. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
9. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2011. PMID: 21837669.
10. Raghav KP, Makkuni P, Figueredo VM. A review of electrocardiography in pulmonary embolism: recognizing pulmonary embolus masquerading as ST-elevation myocardial infarction. Rev Cardiovasc Med 12(3):157-63, 2011. PMID: 22145193.

Invited Articles

1. Raghav KP, Gonzalez-Angulo AM, Blumenschein GR. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Translational Lung Cancer Research 1(2):179-193, 2012.
2. Raghav KP, Eng C. Role of MET/HGF Axis in Colorectal Cancer: Precepts and Prospects. Colorectal Cancer 1(4):329-341, 2012.
3. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs 20(6):859-69, 2011. e-Pub 2011. PMID: 21534718.

Manuals, Teaching Aids, Other Teaching Publications

1. Raghav KP. NEJM Knowledge+. The New England Journal of Medicine, 2014.

Other Articles

1. Pande SA, Raghav K, Mehta S, Babbar G, Kandpal S A woman with a swollen uvula. Cleve Clin J Med 79(9):600-1, 2012. PMID: 22949339.

Editorials

1. Raghav KP, Gonzalez-Angulo AM. Commentary on: Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Breast Diseases: A Year Book Quarterly 22(2):156-158, 2011.

Abstracts

1. Raghav KP, Mhadgut H, Lei X, Overman MJ, Ross A, Renato L, Raber M, Varadhacahry GR. Cancer of unknown primary in adolescents and young adults: Clinicopathologic features, prognostic factors, and survival outcomes. ASCO Annual Meeting 2014, 2014.
2. Raghav KP, Amin HM, Wang W, Manyam GC, Broom B, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. ASCO Annual Meeting 2013, 2013.
3. Raghav KP, Amin HM, Wang W, Manyam GC, Broom B, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. Gastrointestinal Cancer Symposium 2013, 2013.
4. Raghav KP, Kalil K, Ferrarotto R, George B, Eng C, Garrett C, Loyer EM, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. ASCO Annual Meeting 2012, 2012.
5. Raghav KP, Kazmi SMA, Shetty AV, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Uncovering the clinicopathological and mutational profile of appendiceal adenocarcinomas. Gastrointestinal Cancer Symposium 2012, 2012.
6. Raghav KP, Kalil K, Ferrarotto R, George B, Eng C, Garrett C, Loyer EM, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. Gastrointestinal Cancer Symposium 2012, 2012.
7. Raghav KP, Wang W, Liu S, Chavez-Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein Jr. GR, Gonzalez-Angulo AM. Expression of cMET and phospho-cMET in breast cancers by subtype and impact on survival outcomes. AACR San Antonio Breast Cancer Symposium 2011, 2011.
8. Raghav KP, Liu DD, Matrana MR, Bekele BN, Valero V, Ibrahim NK. Nomogram for predicting development of brain metastasis in patients with inflammatory breast cancer. ASCO Breast Cancer Symposium 2011, 2011.
9. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin AA, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. ASCO Annual Meeting 2011, 2011.
10. Raghav KP, Codolosa N, Tester W. Development of second malignancy in a patient with a history of retinoblastoma: A fresh look at the two hit hypothesis. Annual Meeting PA Chapter of ACP 2008, 2008.

Book Chapters

1. Raghav KP, Raber M, Varadhachary GR. Cancer of Unknown Primary Site. In: Clinical Decision Support: ONCOLOGY, 2015.
2. Raghav KP, Varadhachary GR. Favorable Subsets Among Cancers of Unknown Primary. In: Textbook of carcinoma of unknown primary. 1. Springer publishing house: Heidelberg, Germany, 2015.
3. Raghav KP, Gilbert MR. Ependymomas. In: Neuro-oncology. First. Blackwell Publishing Ltd: Oxford, UK, 86-94, 2012.
4. Raghav KP, Katz MH, Overman MJ. Cancers of the Small Bowel. In: Textbook of Uncommon Cancer. Fourth. John Wiley & Sons, Inc: Hoboken, NJ, USA, 4441-451, 2012.

Letters to the Editor

1. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist 20: e3-4, 2015.
2. Raghav KP, Taggart MW, Fournier KF, Overman MJ. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?. J Am Coll Surg 212: 906; author reply 907, 2011.